ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements
Titan Biotech Ltd reported revenue from operations of ₹76.5 Cr (+40.6% YoY) and net profit of ₹12.5 Cr (+60.3% YoY) for Q2 FY27.
Titan Biotech's board meets 05 November 2026 to consider unaudited quarterly and half-year results. Trading window stays closed until 48 hours after outcome declaration.
Titan Biotech allotted 1,03,29,625 bonus shares of Rs. 2 each in a 1:4 ratio. Paid-up capital rose to Rs. 10.33 Crore post-allotment.
Titan Biotech Limited has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Titan Biotech Ltd fixed October 23, 2026, as the record date for its 1:4 bonus share issue. Allotment is scheduled for October 26, 2026.
Titan Biotech increased its authorised share capital from Rs. 10 Crore to Rs. 10.40 Crore, following shareholder approval at the 34th Annual General Meeting.
Titan Biotech Limited held its 34th Annual General Meeting on September 29, 2026. The meeting transacted ordinary and special business, including financial adoption and director appointments.
Titan Biotech has dispatched letters to shareholders with unregistered emails, providing web links to access the FY 2025-26 Annual Report and 34th AGM Notice.
Titan Biotech filed its 34th Annual Report and AGM Notice for the financial year 2025-26. The AGM is scheduled for September 29, 2026.
Titan Biotech Limited has fixed September 22, 2026, as the record date for a final dividend of ₹0.50 per share. The payout remains subject to shareholder approval.
Titan Biotech Limited will hold its 34th Annual General Meeting on September 29, 2026. The company set September 22, 2026, as the record date for final dividend eligibility.
Titan Biotech Limited approved a 1:4 bonus issue and increased its authorised share capital to Rs. 10.40 Crore. The bonus issue is subject to shareholder approval at the upcoming AGM.
Titan Biotech Ltd has scheduled a board meeting on September 3, 2026, to consider a bonus share issue and plan the 34th Annual General Meeting.
Titan Biotech Ltd reported revenue from operations of ₹59.2 Cr (+27.3% YoY) and net profit of ₹10.9 Cr (+58.0% YoY) for Q1 FY27.
Titan Biotech Ltd will hold a board meeting on August 13, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.
Titan Biotech reported loss of 300 shares previously transferred to the IEPF. Claims must be submitted within 15 days as per Regulation 39(3).
Titan Biotech Ltd board approved re-appointing M/s Sanjay Kumar Garg & Associates as Cost Auditors for FY 2026-27. The appointment remains subject to shareholder ratification.
Titan Biotech Ltd reported revenue from operations of ₹48.8 Cr (+38.6% YoY) and net profit of ₹6.7 Cr (+67.5% YoY) for Q4 FY26.
Titan Biotech Limited approved its audited financial results for the fiscal year ended March 31, 2026. The Board also recommended a dividend of Rs. 0.50 per share.
Titan Biotech Limited scheduled a board meeting for May 30, 2026, to approve annual audited financial results and recommend dividends. Trading remains closed until June 1.
Titan Biotech Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report, issued by practicing company secretary Mr. Amit Anand, confirms the company's compliance with SEBI regulations and secretarial standards.
Titan Biotech Limited confirmed it is not classified as a Large Corporate for the financial year ended March 31, 2026. The company reported zero outstanding long-term borrowings under the SEBI framework. This annual disclosure is a routine compliance requirement for listed entities regarding debt market borrowing norms.
Titan Biotech Ltd submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, Beetal Financial, confirmed that security certificates received for dematerialization were processed, cancelled, and substituted in the register of members within the mandated 15-day timeline.